Agonists of the nuclear receptor PPARγ are therapeutically used to combat hyperglycaemia
associated with the metabolic syndrome and type 2 diabetes. In spite of being effective in …

Drug-induced hepatic injury accounts for more than 50 percent of cases of acute liver failure
in the United States. More than 75 percent of idiosyncratic drug reactions result in liver …

METHODS—A Medline search without limitations of date (as of October 2005), language, or
humans was carried out by the authors. The following medical subject headings were …

Drug-induced liver injury (DILI) is common and nearly all classes of medications can cause
liver disease. Most cases of DILI are benign, and improve after drug withdrawal. It is …

Diabetes mellitus type 2 is a world-wide growing health problem affecting more than 150
million people at the beginning of the new millennium. It is believed that this number will …

▪ Abstract Peroxisome proliferator-activated receptor gamma (PPARγ) is a nuclear receptor
involved in the control of metabolism. Research on PPARγ is oriented towards …

Background Drug toxicity is the leading cause of acute liver failure in the United States.
Further understanding of hepatotoxicity is becoming increasingly important as more drugs …

Nonalcoholic fatty liver disease is now recognized as the most common liver disease in the
United States, with a prevalence of approximately 5% in the general population and up to …

Background: Obesity is often associated with nonalcoholic fatty liver disease (NAFLD),
which refers to a large spectrum of hepatic lesions including fatty liver, nonalcoholic …

The spectrum of drug-induced liver injury (DILI) is both diverse and complex. The first step in
diagnosis is a suspicion of DILI based on careful consideration of recent comprehensive …